LENZ Therapeutics to Present at Upcoming Investor Conferences
Rhea-AI Summary
LENZ Therapeutics (NASDAQ: LENZ), a pre-commercial stage biopharmaceutical company developing aceclidine-based eye drops for presbyopia, has announced its participation in three major upcoming investor conferences in June 2025:
- William Blair Growth Stock Conference on June 3 in Chicago (presentation at 1:40pm EDT)
- Jefferies Global Healthcare Conference on June 4-5 in New York City (presentation at 9:55am EDT)
- Goldman Sachs Global Healthcare Conference on June 9 in Miami Beach (fireside chat at 4:00pm EDT)
Live webcasts for the Jefferies and Goldman Sachs presentations will be available on LENZ's website, with replays accessible for 12 months. The company will also conduct one-on-one investor meetings at all three conferences.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, LENZ gained 4.35%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences:
William Blair 45th Annual Growth Stock Conference
Date: June 3, 2025
Location: Chicago, IL
Format: Management presentation at 1:40pm EDT and 1x1 investor meetings
Jefferies Global Healthcare Conference
Date: June 4-5, 2025
Location: New York City, NY
Format: Management presentation at 9:55am EDT (live audio webcast) and 1x1 investor meetings
Goldman Sachs 46th Annual Global Healthcare Conference
Date: June 9, 2025
Location: Miami Beach, FL
Format: Fireside chat at 4:00pm EDT (live audio webcast) and 1x1 investor meetings
Live audio webcasts of the Jefferies Global Healthcare presentation and Goldman Sachs 46th Annual Global Healthcare fireside chat will also be available on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 12 months following the event.
About LENZ Therapeutics
LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ’s product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.
Contacts:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com
FAQ
What investor conferences will LENZ Therapeutics (LENZ) attend in June 2025?
What is LENZ Therapeutics' main product in development?
Will LENZ Therapeutics' conference presentations be available online?
What is the current development stage of LENZ Therapeutics?
